Skip to main content

Table 2 Patients in remission at 12 months according to DAS28 and to modified ARA criteria.

From: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

Baseline status Patients in DAS28 remission, n (%) Patients in modified ARA remission, n (%)
DAS28 BIOL (n = 775) CON (n = 255) BIOL (n = 764) CON (n = 256)
>3.2 to 4.0 16 (45.7) 8 (33.3) 9 (26.5) 4 (16.0)
>4.0 to 5.1 33 (26.4) 16 (23.2) 18 (14.3) 10 (14.5)
>5.1 to 6.0 40 (22.1) 10 (13.5) 38 (20.9) 8 (10.8)
>6.0 to 7.0 28 (11.1) 4 (6.3) 25 (10.1) 3 (4.8)
> 7.0 9 (5.0) 1 (4.0) 11 (6.3) 1 (3.8)
Total 126 (16.3) 39 (15.3) 101 (13.2) 26 (10.2)
  1. ARA, American Rheumatology Association; BIOL, patients treated with biologics; CON, patients receiving conventional DMARD treatment (control group); DAS28, disease activity score based on 28 joint counts.